Imugene Ltd (ASX:IMU) has received approval from the Faculty of Medicine, Chiang Mai University of Thailand to start site activation process for the Phase 1b/2 study of its HER-Vaxx immuno-oncology therapy in gastric cancer.
HER-Vaxx is a cancer immunotherapy designed to treat HER-2 positive gastric cancer, a cancer with increased levels of a growth-promoting protein called the HER-2 receptor.
Immuno-oncology is a relatively new but highly promising field that uses the method of activating a patient's immune system against tumour growth.
The approval in Thailand follows approvals from Taipei Veterans General Hospital in Taiwan and the University of Hong Kong.
Thailand, Taiwan and Hong Kong and are three of the eight study sites participating in the initial Phase 1b portion of the upcoming Phase 1b/2 study.
The initial Phase 1b will enrol up to 18 patients to be treated with HER-Vaxx in combination with chemotherapy to interrogate three dose levels.
This first stage is to obtain safety, immunogenicity (a measure of how many of the HER-2 antibodies are produced), evaluate the booster schedule and determine the optimal dose to take into the Phase 2 study.
The larger, open label Phase 2 study will enrol around 68 patients randomised into two arms of either HER-Vaxx plus standard-of-care or standard-of-care alone.
Gastric cancer represents an area of high unmet medical need, particularly in Asian countries.
Imugene had $1.6 million in cash as at 30 June 2016.
Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.